BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical ...

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...

BioVersys & Shionogi ink global research collaboration for broad-spectrum NTM clinical candidate: Basel, Switzerland Thursday, July 3, 2025, 10:00 Hrs [IST] BioVersys AG, a multi- ...

Japanese drugmaker Shionogi (OTCPK:SGIOY) said a Phase 3 study has shown its antiviral drug Xocova was effective in reducing the risk of developing symptomatic COVID-19 infection in those exposed ...

Japan's Shionogi & Co Ltd believes its COVID-19 pill will easily garner $2 billion in annual sales if it secures U.S. approval, which the company expects to receive in late 2024, its chief ...

Shionogi & Co. shares fell sharply Thursday morning after a panel at Japan’s Ministry of Health, Labor and Welfare decision yesterday that its pill to treat Covid-19 wasn’t ready for emergency ...

Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to ...

Ad hoc announcement pursuant to Art. 53 LR. BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) --The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to ...